Will AstraZeneca plc, Burberry Group plc And Taylor Wimpey plc Be This Year’s Big Winners?

Should you pile into these 3 stocks right now? AstraZeneca plc (LON: AZN), Burberry Group plc (LON: BRBY) and Taylor Wimpey plc (LON: TW).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in house builder Taylor Wimpey (LSE: TW) were given a boost today after the company released an upbeat trading update. It states that against the backdrop of a positive UK housing market, Taylor Wimpey has been able to increase home completions by 7% to 13,341, with the average selling price on private completions increasing by 9% to £254,000.

The latter has benefitted from the company’s focus on better quality locations and with Taylor Wimpey having a record year-end order book, it appears to be well-positioned to post further gains in 2016.

Encouragingly, Taylor Wimpey has also delivered a record operating margin with it now standing at 20%. This, plus an improved outlook for the company’s Spanish division, means that Taylor Wimpey’s outlook is very positive.

In fact, its bottom line is forecast to rise by 15% in the current year. This puts the company’s shares on a price-to-earnings growth (PEG) ratio of only 0.8, which indicates that strong gains could lie ahead for the company’s investors, with a dividend yield of 5.7% highlighting Taylor Wimpey’s income appeal too.

High yields

Also offering a top-notch outlook for income-seeking investors is AstraZeneca (LSE: AZN). Despite a challenging period that has seen its bottom line come under considerable pressure as a result of the loss of patent protection on numerous key drugs, AstraZeneca has maintained dividend payouts over the last five years. And with it currently yielding 4.3%, it offers a higher yield than the wider index at the present time.

Looking ahead, AstraZeneca has significant total return potential. As well as a strong yield, it’s expected to return to positive profit growth in the coming years as its vast acquisition strategy begins to bear fruit. On this front, AstraZeneca has more potential in 2016 and beyond since its cash flow and balance sheet appear able to accommodate substantially more debt. That means it can make further purchases in order to enhance the company’s drug pipeline.

This, alongside a price-to-earnings (P/E) ratio of just 16.3, indicates that now could be an opportune moment to buy a slice of AstraZeneca ahead of improved performance in 2016 and beyond.

China syndrome?

Meanwhile, 2016 has got off to a poor start for luxury fashion brand Burberry (LSE: BRBY). Its shares have been affected by fears surrounding China’s long-term growth rate since the world’s second-largest economy remains a key growth region for Burberry. Therefore, further turbulence in the Chinese stock market could cause a further deterioration in Burberry’s share price after its 7% decline since the turn of the year.

But in the longer term, Burberry has huge growth potential. That’s because it continues to enjoy a relatively wide economic moat as a result of a high degree of customer loyalty. And with a diverse geographical spread, its reliance on China for long-term growth may not be as strong as is currently perceived by the market. Therefore, Burberry may be able to command a higher rating than its current P/E ratio of 14.3 – especially since it’s forecast to return to positive profit growth in the next financial year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca, Burberry, and Taylor Wimpey. The Motley Fool UK has recommended AstraZeneca and Burberry. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing For Beginners

Here’s how I’m trying to prevent a stock market crash from ruining my portfolio

Jon Smith explains which shares he's avoiding and what he's thinking of buying to try and protect his portfolio from…

Read more »

Bearded man writing on notepad in front of computer
US Stock

Call me crazy, but here’s why I’m eyeing up the CrowdStrike share price

Jon Smith notes the carnage caused by Friday's global outage, but flags up why he's thinks the CrowdStrike share price…

Read more »

Investing Articles

What do Hargreaves Lansdown results mean for the share price?

The Hargreaves Lansdown share price has surged in recent months on takeover expectations, but what will the recent results mean…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Newly minted S&P 500 stock CrowdStrike just crashed! Here’s why

Shares of S&P 500 firm CrowdStrike collapse as the company lies at the centre of a global IT outage. What…

Read more »

artificial intelligence investing algorithms
Investing Articles

Is Nvidia heading for the mother of all tech stock crashes?

Nvidia stock has soared, and the company briefly became the most valuable on the planet. But not everyone’s an AI…

Read more »

Dividend Shares

The BP share price is down 15% in 3 months. Time to buy?

In the space of just a few months, the BP share price has fallen by a double-digit percentage. Is this…

Read more »

Investing Articles

A 5.4% dividend bargain I’ll buy over Lloyds shares

Harvey Jones loves his Lloyds shares but now he's found a high-yielding FTSE 250 stock that may offer even more…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Recommended by Warren Buffett, this top hedge fund’s betting on Rolls-Royce shares

When Warren Buffett ended his previous investment partnership, he recommended Bill Ruane’s Sequoia Fund. Today, its largest investment is in…

Read more »